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Summary
Objective: To investigate whether type II collagen turnover markers used for osteoarthritis (OA) activity evaluation in body ﬂuids can be
detected at the level of speciﬁc histological features of OA cartilage tissue, as well as how they relate with each other at this level.
Methods: Adjacent sections were obtained from full-depth cartilage biopsies from 32 OA knees. Immunohistochemistry was performed for
Helix-II and CTX-II, which are type II collagen fragments originating from the triple helix and the telopeptide region, respectively, and believed
to reﬂect distinct breakdown events, as well as for type IIA N propeptide (PIIANP), a biochemical marker reﬂecting synthesis of type IIA collagen.
Results: Helix-II and CTX-II were detected in areas where collagen damage was reported previously, most frequently around chondrocytes,
but also frequently in regions not previously investigated such as the margin area and close to subchondral bone, including vascularization
sites and boneecartilage interface. The latter is CTX-II’s prevailing position and shows rarely Helix-II. PIIANP co-localized with Helix-II and
CTX-II on a limited number of features, mainly in deep zone cartilage. Overall, our analysis highlights clear patterns of association of the
markers with speciﬁc histological features, and shows that they spread to these features in an ordered way.
Conclusion: Helix-II andCTX-II show to somedegree differential selectivity for speciﬁc features in cartilage tissue. CTX-II detection close to bone
may be relevant to the possible role of subchondral bone in OA. The restricted co-localization of breakdown markers and PIIANP suggests that
collagen fragments can result only partially from newly synthesized collagen. Our study strengthens the interest for the question whether com-
bining several markers reﬂecting different regional cartilage contributions or metabolic processes should allow a broader detection of OA activity.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a very common joint disease in the
western world. It is characterized by loss of articular carti-
lage accompanied to some degree by synthesis of matrix
molecules. These processes result in morphological
changes, malfunction of the joint and morbidity. Changes
occur in all the regions of articular cartilage, and are showing
up in a variety of ways, used for grading the disease1. The
cell responsible for elaborating and maintaining the carti-
lage matrix is the chondrocyte, which therefore responds
speciﬁcally to the local needs by performing both catabolic
and anabolic activities. The reason why the chondrocytes
fail to comply with these tasks in OA is not understood,
and there is presently no therapy targeting chondrocytes
and preventing OA. Much information was, however, gained*Address correspondence and reprint requests to: Dr. Jean-Marie
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615on the molecular changes occurring in the cartilage matrix
during OA development2.
The cartilage matrix is composed mainly of proteoglycans
and type II collagen ﬁbrils. It is proposed that damage to the
collagen network leads to loss of tensile strength, and is
a critical event in OA2,3. An elegant approach for assessing
this damage was based on immunoreactive probes recog-
nizing neoepitopes in the unwound triple helix of the colla-
gen molecule2,4e7. This approach showed a correlation
between unwound collagen and collagen/proteoglycan
content of cartilage, and it also showed that this collagen
damage starts at the articular surface and around the
chondrocytes, and then progresses to deeper zones. These
probes did not detect collagen damage in areas close to the
subchondral bone, despite the possible role of subchondral
bone in OA8,9. Interestingly, these probes have all in com-
mon that they recognize damage initiated by collagenases6,
which are proteinases able to cleave the native triple helix
of collagen. This property of these probes, together with
their co-localization with collagenases in histological sec-
tions10 and the inhibition of collagen damage upon treat-
ment with collagenase inhibitors11,12 led to the view that
collagenases may play a key role in OA. On the other
616 A.-C. Bay-Jensen et al.: Collagen turnover markers in cartilage tissuehand, however, inhibition by these collagenase inhibitors
was often partial, suggesting that other proteinases may
contribute to collagen cleavage11. Accordingly, chondro-
cytes and cells of other tissues of the joint were reported
to express proteinases with different cleavage speciﬁcities
toward collagen compared with collagenases, and able to
attack collagen at the level of its telopeptides or of destabi-
lized triple helices13e17. These included matrix metallopro-
teinases, such as MMP-9 and MMP-3, and a series of
cysteine dependent cathepsins, such as cathepsin K, B,
L, and S. To our knowledge, human articular cartilage sec-
tions have not yet been probed for collagen breakdown by
these other proteinases, and possible damage to the colla-
gen network due to these proteinases has not been identi-
ﬁed within the cartilage joint.
A series of studies of disease activity in OA are based on
the urinary levels of CTX-II, a fragment arising from the
telopeptide region of type II collagen, and that can be gen-
erated by the action of several of the non-collagenase
proteinases mentioned above13,18,19. In patients with knee
or hip OA, elevated urinary levels of CTX-II correlated with
radiographic scores including joint space narrowing, joint
surface, joint pain, joint inﬂammation, and bone sclero-
sis20e23. Furthermore, CTX-II levels responded to a number
of factors/conditions considered to affect speciﬁcally bone,
such as bisphosphonates, calcitonin, selective estrogen
receptor modulators (SERMs), or postmenopausal sta-
tus19,24e27 thereby reﬂecting possibly to some degree the
suspected boneecartilage interactions in OA develop-
ment8. In contrast, the menopausal status did not induce in-
creased release of fragments arising from the helix part of
type II collagen into body ﬂuids2,28. One of them, Helix-II,
was compared to CTX-II in the same OA patients, and de-
spite the fact that both were elevated they correlated only
weakly with each other14,29. This suggests that Helix-II
and CTX-II reﬂect distinct biological/enzymatic pathways
of cartilage collagen degradation. The question of the asso-
ciation of CTX-II and Helix-II with distinct events in cartilage
tissue remained, however, to be investigated.
Finally, several studies addressed the question of colla-
gen synthesis in articular cartilage. In situ hybridization
and immunohistochemistry of type II collagen propeptides
showed intense focal staining in OA cartilage, particularly
away from the areas showing damaged matrix, whereas
collagen synthesis was not detected in cartilage from
healthy patients30e32. Both the C and N propeptides
showed similar results. Of particular interest is that the N
propeptide corresponds to the fetal splice variant, type IIA
N propeptide (PIIANP), indicating the potential reversion
of the cells to a chondroprogenitor phenotype possibly aim-
ing at matrix repair32. However, serum levels of PIIANP and
of the C-terminal propeptide, PIICP, were decreased in OA
patients compared with healthy controls31,33,34, thereby
showing an apparent discrepancy with the observations at
the tissue level. Furthermore, decreased levels of PIIANP
corresponded with increased levels of CTX-II monitored in
the same study, and were therefore interpreted as uncou-
pling of collagen type II synthesis and degradation33. The
question of the inter-relation of collagen synthesis and
breakdown at the level of the same cartilage feature has,
however, not been addressed.
There is thus insufﬁcient knowledge on the association of
possibly different collagen breakdown mechanisms with
distinct OA events, as well as on their relation with collagen
synthesis. Furthermore, it has insufﬁciently been investi-
gated which speciﬁc tissue alterations are reﬂected by clin-
ical markers of collagen turnover measured in body ﬂuids.In the present study, we probe full-depth sections of OA car-
tilage with clinical markers of (1) type II collagen degrada-
tion arising from the helix domain, Helix-II; (2) from the
telopeptide domain, CTX-II; and (3) of collagen synthesis,
and analyzed their association with speciﬁc histological fea-
tures. This analysis demonstrates clear patterns of associ-
ation/dissociation of each of these markers with each
other, and with OA histological events.Materials and methodsPATIENTSCartilage samples from 50 OA knees were collected from patients under-
going total knee replacement according to an approved clinical protocol.
Brieﬂy, all patients were postmenopausal women [mean age 65.3 years
(11.2 standard deviation [SD])] who had not received hormone replacement
therapy; were not diagnosed for any other endocrinological, metabolic or
bone-related disorders; were not severely overweight (body mass index
[BMI]< 35); had less than 4 h of physical activity per week. Collection of tis-
sue specimens was approved by the Danish ethical committee, and all OA
patients signed an informed consent formula. All patients were diagnosed
with total knee OA. The degree of OA was graded by experienced orthopedic
surgeons prior to surgery by Ahlba¨ck’s X-ray classiﬁcation35 and postsurgery
by visual Outerbridge scoring36. All patients included in the study were
graded an Ahlba¨ck score between 3 and 5 for and an Outerbridge score of
3 or 4 of the worst affected position of knee.TISSUE PREPARATIONKnee discards were recovered immediately after surgery in sterile condi-
tions. Biopsies were cut from both lateral and medial sides of femur condyles
and tibia plateau including the loading zone, as well as the margin zone
whenever possible (Fig. 1). All biopsies were ﬁxed in 10% buffered formalin
for 48 h at room temperature (RT) and decalciﬁed in 0.2 M Idranal III solu-
tion (Riedel-van Ha¨en, SigmaeAldrich, Denmark) under constant agitation at
RT for up to 4 weeks depending on the biopsy. They were then processed
according to standard pathological procedures, embedded in parafﬁn, and
cut longitudinally so as to show full-depth cartilage from the joint surface to
subchondral bone, as well as whole area from the loading toward the mar-
ginal zone (Fig. 1). Adjacent sections (5 mm) were obtained and mounted
on positive Superfrost glass slides (Hounisen, Denmark).HISTOPATHOLOGICAL GRADINGSections were deparafﬁnized, hydrated and one section from each patient
was stained with an optimized fast greeneSafranin O (FGSO) trichrome
staining protocol37,38. Brieﬂy, sections were incubated for 10 min in Mayer’s
acidic hematoxylin (SigmaeAldrich, Denmark), rinsed in tap water, incubated
for 10 min in 0.001% Fast Green FCF (SigmaeAldrich, Denmark) solution,
rinsed in 1% acetic acid and incubated 20 min in 0.1% Safranin O
(SigmaeAldrich, Denmark) solution. Next the slides were rinsed and dehy-
drated in a series of distilled water, alcohols and xylene, and mounted in Per-
tex mounting medium (Sakura Prohosp, Denmark). All biopsies were graded
according to the Mankin score38,39. Biopsies scoring middle or late phase
(Mankin 4e10) OA were included in the study, while biopsies scoring early
(Mankin< 4) or terminal phase (Mankin> 10) OA were excluded, because
of lack of OA features of interest. In this way, a total of 58 biopsies were
analyzed (13 lateral femur, 13 medial femur, 18 lateral tibia, and 14 medial
tibia biopsies). These biopsies correspond to 32 knees, 26 of which were
from patients diagnosed with primary OA, and six of which had been sub-
jected to injuries including menisectomy, fracture, and rupture of the cruciate
ligament. The OA type of each biopsy is shown in Fig. 4.IMMUNOHISTOCHEMISTRYFor immunodetection of Helix-II, we used the polyclonal rabbit antibody
which recognizes the ERGETGPhypGTS sequence from the helical region
and was previously described14. For immunodetection of PIIANP we used
the polyclonal rabbit antibody which has been previously described and
used in immunochemistry experiments32,40,41. For immunodetection of
CTX-II we used a new polyclonal rabbit antibody raised against the six
amino-acid sequence (EKGPDP) of the C telopeptide of type II collagen.
Competition experiments using synthetic peptides show that the antibody
recognizes speciﬁcally this amino-acid sequence and the recognition is de-
pendent on the presence of a proline at the C-terminal end. This antibody
does not recognize un-cleaved type II collagen, or homologous sequences
Fig. 1. Schematic view of a typical biopsy section used in the present study. The ﬁgure is aiming at deﬁning the distinct areas and histological
features of OA cartilage, mentioned in the present study. Note that ‘‘ﬂat chondrocytes’’ are positioned close to the surface of the joint. ‘‘Column
chondrocytes’’ appear in stacked lacunas in the deep zone above the tidemark. Vascularization appears in deep zone cartilage areas, as
invasion into calciﬁed cartilage and even further through the tidemark.
617Osteoarthritis and Cartilage Vol. 16, No. 5from type I and III collagens. The demasking procedure and antibody con-
centrations were optimized to give optimal visualization of the antigen, and
no background signals as evaluated by using pre-immune serum at the
same concentration. Staining with Helix-II and PIIANP followed the same
procedure and was based on typical peroxidase coloring and tyramide en-
hancement. Sections were deparafﬁnized, blocked for endogen peroxidase
with H2O2 for 30 min in 99% ethanol and then hydrated. Sections were
then demasked by overnight incubation (8e13 h) at 63C in citrate buffer
(pH 6.0) or for 2 h in Triseethylenediamine tetraacetic acid buffer (pH 9.0)
at 80C. Sections were blocked in 0.5% casein and for endogenous biotin
according to DAKO (Denmark). Sections were then incubated for 2 h at
RT with antibody against Helix-II (diluted 1:4000), or CTX-II (diluted
1:3000), or PIIANP (diluted 1:1500). This incubation was followed by a
30-min incubation with horseradish peroxidase (HRP) conjugated antirabbit
polymer (EnVisionþ, DAKO, Denmark). Sections were tyramid-enhanced
by incubating for 10 min with biotinylated tyramide and for 30 min with
HRP conjugated streptavidin. Development was performed using diamino-
benzidine tetrahydrochloride (DAB+) (DAKO, Denmark), enhanced with
CuSO4. Finally the sections were counter-stained with Mayer’s acidic hema-
toxylin, dehydrated, and mounted in Pertex. Digital pictures were obtained
using a computer assisted microscope and only modiﬁed by enhancing the
contrast and light; no background was removed or altered.SCORING OF IMMUNOSTAININGS AND STATISTICSEight adjacent sections were taken from each biopsy. Two were stained
with FGSO in order to identify histological areas of interest, while the others
were immunostained for CTX-II, Helix-II, and PIIANP, in duplicate to assess
reproducibility. They were analyzed with a 10 or 20 objective. The
number of biopsies where given histological features were identiﬁed was
counted. For each feature, the presence or absence of the respective
markers was recorded. Only clear signals as shown in Fig. 2 were taken
into account. The frequency of biopsies showing an association of the re-
spective markers with each of the features was determined. Furthermore,
the statistical signiﬁcance of co-localizations of markers was analyzed by
Fisher’s exact test, testing whether the detection of a given marker increased
signiﬁcantly the chance to detect also another marker.
ResultsTYPICAL FEATURES APPEARING UPON STAINING WITH FGSO
AND ANTIBODIES AGAINST COLLAGEN TURNOVER MARKERSUpon FGSO staining, the biopsies showed well-known
characteristics of OA cartilage (Fig. 1), including loss of pro-
teoglycan in the upper and midzone cartilages [Fig. 2(A,B)],
ﬁbrillated surfaces [Fig. 2(B)], clustered chondrocytes
[Fig. 2(C)], and vascular invasions [Fig. 2(D)]. Actually, oneor several of these features were present in at least 90% of
the biopsies (Fig. 3). These biopsies showed also areas with-
out morphological damage, such as deep zone and margin
area cartilage [Fig. 2(E)]. Upon immunostaining, the biopsies
showed immunoreactivity for the collagen degradation
markers, Helix-II and CTX-II, as well as for the collagen syn-
thesis marker, PIIANP, which all are used to assess OA
throughmeasurements in body ﬂuids. Figure 2 shows typical
examples of how these immunoreactivities appear, whether
associated with chondrocytes [Fig. 2(AeF)] or with matrix
[Fig. 2(B,D,F)], or occurring close to [Fig. 2(BeD)] or away
from lesions [Fig. 2(E,F)]. Because of the heterogeneity of
OA, and also because immunostaining intensity is not a reli-
able quantiﬁcationmethod, we chose to analyze these immu-
nostainings by determining their frequency of association
with given histological features.OVERALL ANALYSIS OF THE DISTRIBUTION OF COLLAGEN
TURNOVER MARKERSFigure 3 gives an overview of how frequently Helix-II,
CTX-II, or PIIANP immunoreactivity was detected in the dif-
ferent cartilage areas. These immunoreactivities were widely
distributed over the different regions, including deep zone
cartilage and margin cartilage, i.e., regions appearing non-
damaged, and located sometimes far away from where
lesions are seen. They also showed a clear pattern of asso-
ciation of immunoreactivity with speciﬁc histological features
of these cartilage regions. Immunoreactivities were associ-
ated most frequently with chondrocytes (in 60e80% of the
biopsies in the case of Helix-II), and this holds true whether
the chondrocytes are positioned in the upper, middle, deep,
or lateral zone, andwhether they are organized in single lacu-
nae, in clusters, or in columns. In contrast, immunoreactivity
ismore rarely detected in interterritorial matrix, whether in the
mid or deep zone and whether calciﬁed or not, and despite
frequent evidence for loss of proteoglycan in the midzone.
However, matrix associated immunoreactivity appeared
quite frequently in specialized areas of the matrix, such
as superﬁcial matrix, ﬁbrillated matrix, margin matrix, the
boneecartilage interface, and sites of vascularization. As
Fig. 2. Examples of histological appearance and immunoreactivity of Helix-II, CTX-II andPIIANP in different areas ofOAcartilage.Different areas
ofOA cartilage (rowsAeG)were stained as indicated (columns IeV). (A) Superﬁcial area. Toward the surface chondrocytes are ﬂat, andSafranin
O staining (red) is absent, indicating loss of proteoglycan. Flat chondrocytes are positive for Helix-II, CTX-II and PIIANP (arrowheads). Note that
the interterritorial matrix does not show any immunoreactivity despite the loss of proteoglycan, but surface is positive for CTX-II. (B) Fibrillated
superﬁcial area. Absence of Safranin O in the ﬁbrillated zone indicates loss of proteoglycan. The ﬁbrillated (but not the underlying) matrix and
most chondrocytes are positive for Helix-II, CTX-II, and PIIANP. (C) Midzone area showing clonal chondrocytes and Safranin O stained proteo-
glycan (red). Most clonal chondrocytes show Helix-II and some show CTX-II and PIIANP. The matrix does not show any immunoreactivity.
(D) Deep zone area is shown in ﬁve adjacent sections. Note proteoglycan-containing un-calciﬁed and calciﬁed cartilage (dark and light red, re-
spectively), their tidemark separation (purple line), the subchondral bone (blueegreen), and vascular invasion (asterisk in FGSO). The latter
shows Helix-II and PIIANP (inset at higher magniﬁcation), whereas the boneecartilage interface shows CTX-II and no Helix-II and PIIANP (as-
terisk and inset in CTX-II). The interterritorial matrix does not show any immunoreactivity. (E) Proximal margin. Safranin O positive ﬁbrocartilage
(red) and ﬁbrous tissue (blueegreen). Chondrocytes show Helix-II and weak PIIANP immunoreactivity. Their levels are a bit higher at the
cartilageeﬁbrous tissue interface. The proximal margin area is devoid of CTX-II. (F) Distal margin. Note ﬁbrous tissue (grayish blue) with numer-
ous cells, and bone (blueegreen). The cells showhigh levels of Helix-II andPIIANP. The latter is also abundant at the interface betweenbone and
ﬁbrous tissue. The distalmargin area is devoid of CTX-II. Control sections adjacent to the one incubated anti-CTX-II (A,C) andHelix-II (BeF)were
incubated with corresponding pre-immune antibody and did not show immunoreactive signals. Bars: 50 mm.
618 A.-C. Bay-Jensen et al.: Collagen turnover markers in cartilage tissuea matter of fact, frequencies at the latter sites were almost as
high as for chondrocytes.
Figure 3 provides also interesting information about the
relative frequencies of Helix-II, CTX-II and PIIANPimmunoreactivity. Overall, Helix-II is detected the most
frequently and CTX-II the less. Actually in most positions,
Helix-II is detected at least twice as frequently as CTX-II.
However, Helix-II was never detected in calciﬁed matrix
Fig. 3. Frequency of association of marker immunoreactivity with
speciﬁc histological features. Adjacent sections were obtained
from each of the 58 biopsies, and immunostained for Helix-II,
CTX-II, and PIIANP. The distribution of these immunoreactivities
was analyzed, paying attention to the histological features listed
in the graph, and which are shown in three distinct groups according
to the cartilage zone where they are localized. The number of biop-
sies where these features were identiﬁed is shown in the right col-
umn (N ). The number of biopsies showing an association of the
respective markers with each of these features was normalized to
N, and is shown by the length of the bars. For convenience of com-
parison, the features were ranked within each of cartilage zones,
according to increasing frequency of association with Helix-II.
619Osteoarthritis and Cartilage Vol. 16, No. 5while CTX-II was detected at this level. Furthermore, CTX-II
was the prevailing marker at the boneecartilage interface
(positive in about 50% of the biopsies), and was as frequent
as Helix-II at ﬁbrillated surfaces. Note also the peculiarity of
the margin zone showing rather high frequency of PIIANP
relative to Helix-II, and rarely CTX-II.ANALYSIS OF THE DISTRIBUTION OF COLLAGEN TURNOVER
MARKERS IN RELATION WITH THE CHARACTERISTICS
OF THE INDIVIDUAL BIOPSIESThe analysis of Fig. 4 shows that the extent of immunore-
activity through the cartilage tissue was variable, depending
on which biopsy and on which marker is considered. Two
biopsies were completely negative for Helix-II, 16 for CTX-IIand ﬁve for PIIANP, but all the biopsies showed immuno-
reactivity for at least onemarker, and when immunoreactivity
was wide-spread, up to 75%, 50%, and 64% of the analyzed
features were positive for Helix-II, CTX-II, and PIIANP, re-
spectively. The bone origin (femur condyles or tibia plateau)
or joint area (lateral or median) neither affected the extent nor
the position of the immunoreactivity, whatever the marker.
Similarly, the Mankin score in the 5e10 range did not corre-
late with the degree of spreading, but it is remarkable that
the deep zone matrix areas that were positive for Helix-II or
CTX-II or PIIANP, which were only very few, all showed
Mankin score 10. Figure 4 also shows that there is no strict
correlation between Helix-II, CTX-II and PIIANP with respect
to extent of spreading. For example, there are biopsies show-
ing at least ﬁve positive Helix-II features, but no CTX-II at all.
There is, however, no evidence that the spreading of Helix-II
and CTX-II varies in opposite directions, which would have
meant that different proteolytic mechanisms prevail in differ-
ent biopsies. Interestingly, when distribution of immunoreac-
tivity is restricted to one or two features, the three most
frequent ones included clustered chondrocytes of the
upper/midzone and vascularization below the tidemark,
whatever themarker. The third prevailing featurewas the car-
tilageebone interface for CTX-II and single chondrocytes for
Helix-II and PIIANP. In situations where distribution of
immunoreactivity extended to ﬁve features or more, the pre-
vailing positive features included the same as in the biopsies
with restricted immunostaining, plus the ﬂat chondrocytes of
the upper zone, the chondrocytes of the margin, and the
chondrocytes of the deep zone for Helix-II and PIIANP.
Thus this analysis indicates that spreading of immunore-
activity of each of the markers to more features occurs to
some degree in an ordered way, which seems mainly deter-
mined by the intrinsic properties of these features. It also
indicates that amongst these features, somearemainly char-
acterized by a single marker (e.g., boneecartilage interface
for CTX-II); a few show a parallel behavior for only Helix-II
and PIIANP (e.g., the ﬂat and single chondrocytes of the
upper/midzone, chondrocytes of the margin zone, and col-
umn chondrocytes of the deep zone); and a few show a par-
allel behavior for the three markers (e.g., vascularization and
clustered chondrocytes).CO-LOCALIZATION OF COLLAGEN TURNOVER MARKERS
AT THE LEVEL OF GIVEN HISTOLOGICAL FEATURESBecause of the parallel behavior of some of the markers
in Figs. 3 and 4, we analyzed which showed statistically sig-
niﬁcant co-localizations and which features were concerned
by these co-localizations (Table I). Signiﬁcant co-localiza-
tions were found only for a few features. These included
the vascularization sites for the three markers taken 2 by
2; the single chondrocytes for Helix-II/PIIANP and Helix-II/
CTX-II; column chondrocytes for Helix-II/PIIANP, and ﬂat
chondrocytes for Helix-II/CTX-II. In contrast, other positions
that appeared frequently positive for two or three markers
were most often not simultaneously positive for these
markers. This analysis thus suggests that collagen deposi-
tion and breakdown into Helix-II and CTX-II are simulta-
neous at the level of a few well-deﬁned features, but do
not occur simultaneously at the level of most features.Discussion
The present study demonstrates the association of type II
collagen breakdown and synthesis markers with speciﬁc
Fig. 4. Distribution of marker immunoreactivity in each biopsy. The data used for the analysis of Fig. 3 were organized in a table where each
line represents a biopsy, each column represents a feature probed for Helix-II, CTX-II, or PIIANP in three adjacent sections, and each cell
indicates whether immunoreactivity is present (red), absent (green), or could not be detected because the feature was absent in this particular
section (yellow). The number of positive features in each section is shown for the respective markers, and the biopsies were ranked according
to increased spreading of Helix-II immunoreactivity. The three columns to the left indicate the site of origin of the section within the joint (tibia or
femur and lateral or median), as well as the Mankin score assessed in adjacent sections. Patients not diagnosed for primary OA are shown
with an identiﬁcation number on a yellow background in the left column.
620 A.-C. Bay-Jensen et al.: Collagen turnover markers in cartilage tissuehistological features of OA cartilage. These associations
are especially interesting to discuss taking into account
the speciﬁcities of these markers for deﬁned collagen
breakdown products, and the response of their body ﬂuid
levels to disease situations. Also some of the methodologi-
cal aspects used here are unique compared with previous
studies. Of note is (1) the simultaneous assessment oftwo breakdown products and one synthesis marker, as
well as histological features in adjacent sections, thereby
allowing direct comparisons of the association of the
markers with single histological features; and (2) separate
quantiﬁcations of the frequency of these associations for
each of these histological features. This approach allowed
avoiding the ‘‘noise’’ generated by the heterogeneity of
Table I
Co-localization of Helix-II, CTX-II, and PIIANP
Helix-II vs CTX-II Helix-II vs PIIANP CTX-II vs PIIANP
P N P N P N
Midzone matrix 1 57 1 57 1 57
Fibrillated surface 0.227 54 0.087 54 0.018* 53
Superﬁcial matrix 0.300 29 0.269 31 0.298 28
Single chondrocytes 0.009** 53 0.019* 54 0.051 54
Flat chondrocytes 0.039* 33 0.107 33 0.667 31
Clusters 0.060 51 0.457 52 1.000 47
Calciﬁed cartilage e 54 e 54 0.037* 55
Interface cartilage and bone 0.236 55 0.036* 55 0.491 55
Deep zone matrix 0.052 58 0.002** 58 0036* 58
Vascularization through tidemark 0.014* 37 0.038* 37 0.045* 37
Column chondrocytes 0.274 54 0.0003*** 54 0.161 54
Vascularization below tidemark 0.021* 54 0.0004*** 52 0.149 53
Proximal margin matrix 0.912 34 0.113 32 0.781 32
Distal margin cells 0.182 11 0.067 10 0.300 10
Distal margin matrix 0.810 21 0249 20 0.730 20
Proximal margin chondrocytes 0.273 34 0.114 33 0.324 33
The data of Fig. 4 were analyzed for co-localization of the collagen turnover markers with a given feature, by using Fisher’s exact test. The
columns show the P values for the co-localizations of the markers taken 2 by 2, and the number of biopsies involved in this evaluation.
Statistical signiﬁcant co-localizations: *P< 0.05; **P< 0.01; and ***P< 0.001.
621Osteoarthritis and Cartilage Vol. 16, No. 5OA cartilage and distinguishing clear patterns of localization
for each of the markers.
Collagen breakdown in cartilage sections was previously
assessed only with probes detecting collagenase-initiated
cleavage in the triple helix, and they showed prevailing
signals at the articular surface and around chondrocytes,
extending sometimes to the interterritorial matrix, including
deep zone cartilage4e6. In the present study we probed car-
tilage sections with two different probes for collagen frag-
ments: one recognizing a fragment originating from the
type II collagen triple helix like in previous studies although
from a different region, and one originating from the telopep-
tide region of type II collagen for comparison14. These two
probes stained cartilage surface including ﬁbrillated areas
and chondrocytes, just like did the probes used in previous
studies. However, frequently stained areas included also
regions toward the subchondral bone where collagen frag-
mentation signals were not reported previously. This obser-
vation is compatible with the possible role of subchondral
bone in OA8,9. For instance, vascularization sites in the
deep zone cartilage were frequently positive for Helix-II
and CTX-II, even in sections showing restricted immunos-
taining. Furthermore, the cartilageebone interface stained
for CTX-II, not Helix-II, and this was actually CTX-II’s pre-
vailing position, also when immunostaining was restricted.
Also the marginal area showed collagen breakdown, but
in contrast, mostly through Helix-II and not so much through
CTX-II.
It is remarkable that our analysis shows a series of posi-
tions where CTX-II is frequently detected and where Helix-II
is absent or almost, and vice versa. This absence of spatial
correlation between Helix-II and CTX-II in cartilage tissue
may relate to the fact that the body ﬂuid levels of Helix-II
and CTX-II do not correlate well with each other despite
both are elevated in OA patients14,29. Noteworthy, as sus-
pected by O’Kane et al.42, CTX-II prevailed compared to
Helix-II, in areas close to the subchondral bone, such as
the boneecartilage interface or the mineralized matrix.
The latter may relate to the unique response of CTX-II to
agents/situation affecting bone turnover23,25e27. This
includes also the menopause status which correlated withincreased CTX-II19,43 but decreased C2C, a helix epitope2,
and which did not show any signiﬁcant correlation with
Helix-II28. The actual mechanism at the origin of these
differences in Helix-II and CTX-II tissue localizations is un-
clear. As a matter of fact Helix-II and CTX-II originate from
collagen domains known for their different susceptibility
to proteolytic attack14, and test tube experiments have dem-
onstrated that the proteolytic pathways determining the
generation of Helix-II and CTX-II involve very different pro-
teinases13. Thus if different proteinases prevail in cartilage
and bone, one may expect different fragmentation patterns
at the boneecartilage interface compared to further inside
the cartilage. One should also be aware that the respective
positions of Helix-II and CTX-II do not necessarily coincide
with the sites of their generation. They may also relate to the
relative binding strength of these fragments to given histo-
logical features while diffusing away from their site of origin.
As a matter of fact Helix-II and CTX-II should diffuse readily
away from cartilage since their levels in the body ﬂuids of
OA patients proved to be elevated14. This may explain
why they generated low matrix staining. This is in contrast
with previous studies detecting damaged collagen appear-
ing often retained in the tissue5,6,44. The different position
of Helix-II and CTX-II signals may also relate to differences
in susceptibility to destruction. For instance, cathepsin B is
known to degrade Helix-II13 so that the absence of Helix-II
at the boneecartilage interface could be ascribed to the
possible high levels of cathepsin B in these areas, by analogy
with high levels of cathepsin B at the boneecartilage
interface of the growth plate45.
It is also interesting that the chondrocytes are the most
frequently stained feature. Since they are also the site of
type II collagen and proteinase synthesis, one may wonder
whether Helix-II and CTX-II originate partially from newly
synthesized collagen that is rapidly degraded rather than
from the degradation of the matrix collagen network. This
hypothesis was put forward earlier11 and did not prove to
be supported by assessments of collagen synthesis and
breakdownperformed in extracts of full-depth cartilage46. Be-
cause such extracts contain very diverse cartilage tissue that
may generate noise and obscure very localized correlations,
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sessing the immunoreactivity of the fetal propeptide of type
II collagen, PIIANP, separately at the level of different
features and comparing it with Helix-II and CTX-II immunore-
activity at the level of the same features in the adjacent sec-
tion. Our analysis showed similar localization of PIIANP as in
previous propeptide immunolocalization studies31,32 (chon-
drocytes of middle zone and association with the matrix in
the upper zone and deep zone on some occasions), but
also at sites thatwere not reported previously, such as vascu-
larization sites and margin zone. Actually, the latter two sites
together with chondrocytes were those where PIIANP was
most frequently detected, as is also the case for Helix-II.
When analyzing co-localizations statistically, signiﬁcant
correlations between Helix-II and PIIANP were seen for
most of the features of the deep zone, including column chon-
drocytes, vascularization sites, and deep zone matrix. There
was also signiﬁcant co-localization between CTX-II and
PIIANP at the level of some features although to a lower ex-
tent. These co-localizations suggest that Helix-II and CTX-II
may reﬂect partially degradation of newly synthesized colla-
gen at some sites. However, for many features of other
cartilage regions, there was no signiﬁcant co-localization of
Helix-II and PIIANP and even less so for CTX-II and PIIANP,
which may explain the absence of correlation between
CTX-II and PIIANP levels in body ﬂuids31,33,34, as well as
the absence of correlation between PIICP and collagen
breakdown in extracts of full-cartilage sections46.
Collagen turnover markers and Mankin scores correlated
in some studies but not in others5,44,46. Our study did not
show correlations, although the probes we used were
able to detect broader collagenolytic actions than previous
studies. Absence of correlations may be due to the fact
that the Mankin scores of our biopsies were within a too nar-
row range. It may also be due to the fact that the Mankin
scale scores ﬁnal damage that cannot be directly compared
with the early molecular alterations detected with the colla-
gen turnover markers. Furthermore, our analysis stresses
that the response of chondrocytes to the OA condition
was not random as often suggested by the heterogeneity
of OA cartilage, but proceeded in an ordered sequence,
both for breakdown and synthesis markers. In biopsies
with restricted stainings, the positive chondrocytes were
clustered chondrocytes of the upper/middle zone. Upon
spreading of immunoreactivity, ﬂat chondrocytes close to
the surface become also positive, and Helix-II and PIIANP
become also associated with chondrocytes of the deep
zone and the marginal zone. Thus it is in a highly orches-
trated way that the chondrocytes switch to a high collagen
turnover phenotype.
One could wonder whether the present immunostaining
patterns reﬂect the biological reality, or result merely from
technical peculiarities, arguing for instance that the chon-
drocytes are the most frequently stained features because
of the better penetration of the antibodies at this level.
However, as shown in Table I and discussed above, even
cartilage features that are frequently immunostained by
two different markers like chondrocytes show only rarely
simultaneous localizations of these two different markers
in the same biopsy. Thus the factor determining which of
two markers immunostains a feature does not relate to
the intrinsic accessibility of this feature to an antibody, but
is biopsy dependent. It is also of interest to mention that
similar immunostaining patterns were obtained in cryosec-
tions (not shown).
In conclusion, two collagen breakdown probes that were
elevated in body ﬂuids of OA patients could be detected inOA cartilage tissue, thereby providing evidence for their
relevance to cartilage tissue events. These probes show
signs of collagen breakdown at the articular surface and at
the level of chondrocytes as previously detectedwith collage-
nase speciﬁc probes, but also at vascular sites and bonee
cartilage interface where collagen damage was not detected
previously. These latter sites were even amongst the ﬁrst to
be stained when ranking the tissues for increased spreading
of staining. These newly detected locations are compatible
with the suspected role of boneecartilage interactions in
OA. These detections may be ascribed to the fact that we
used probes recognizing fragments generated by protein-
ases with different cleavage speciﬁcities, thereby allowing
the detection of broader distributions. Finally, because of
the limited co-localization of PIIANP with collagen break-
down products, our study supports the view that collagen
breakdown products result only partially from newly synthe-
sized collagen (i.e.,mainly in the deep zone). It remains, how-
ever, to be investigated whether there is a direct correlation
between a speciﬁc immunostaining pattern in given knees
and the level of CTX-II or Helix-II in the body ﬂuids of the cor-
responding OA patient, as well as how the immunoreactivity
would appear in cartilage from a healthy patient.
Overall our study supports the use of Helix-II, CTX-II and
PIIANP levels in body ﬂuids as markers for cartilage colla-
gen turnover in OA. It also supports the hypothesis that
combined measurements of several markers may be re-
quired for evaluating appropriately the damage in cartilage,
but the actual demonstration of this hypothesis still requires
a clinical study addressing directly this question.
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